Last updated on March 2020

S0820 Adenoma and Second Primary Prevention Trial


Brief description of study

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.

Detailed Study Description

The purpose of this study is to assess whether the combination of eflornithine 500 mg and sulindac 150 mg (compared to corresponding placebos) has efficacy against colorectal lesions with respect to high-grade dysplasia, adenomas with villous features, adenomas 1 cm or greater, multiple adenomas, any adenomas >/= 0.3 cm, total advanced colorectal events, or total colorectal events.

Clinical Study Identifier: NCT01349881

Find a site near you

Start Over

Highland General Hospital

Oakland, CA United States
3.01miles
  Connect »

Bay Area Tumor Institute

Oakland, CA United States
5.04miles
  Connect »

Hematology and Oncology Associates-Oakland

Oakland, CA United States
5.04miles
  Connect »

Tom K Lee Inc

Oakland, CA United States
5.04miles
  Connect »

Bay Area Breast Surgeons Inc

Emeryville, CA United States
5.36miles
  Connect »

Epic Care Partners in Cancer Care

Emeryville, CA United States
5.36miles
  Connect »

Kaiser Permanente San Leandro

San Leandro, CA United States
5.48miles
  Connect »

Kaiser Permanente-Oakland

Oakland, CA United States
5.76miles
  Connect »

East Bay Radiation Oncology Center

Castro Valley, CA United States
9.96miles
  Connect »

Eden Hospital Medical Center

Castro Valley, CA United States
9.96miles
  Connect »

Valley Medical Oncology Consultants-Castro Valley

Castro Valley, CA United States
9.96miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.